PBH:NYE-Prestige Brand Holdings Inc. (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 69.67

Change

+1.32 (+1.93)%

Market Cap

USD 2.60B

Volume

0.45M

Analyst Target

USD 45.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Prestige Brands Holdings Inc is engaged in the marketing, sales and distribution of well-recognized, brand name OTC healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-19 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-0.74 (-0.46%)

USD 66.94B
TAK Takeda Pharmaceutical Co Ltd A..

+0.11 (+0.84%)

USD 41.54B
HLN Haleon plc

-0.18 (-2.11%)

USD 37.53B
TEVA Teva Pharma Industries Ltd ADR

-0.07 (-0.50%)

USD 15.97B
RDY Dr. Reddy’s Laboratories Ltd..

+0.51 (+0.69%)

USD 11.85B
CTLT Catalent Inc

+0.15 (+0.27%)

USD 10.04B
ELAN Elanco Animal Health

-0.01 (-0.08%)

USD 6.40B
PRGO Perrigo Company PLC

+0.24 (+0.73%)

USD 4.26B
EVT Eaton Vance Tax Advantaged Div..

-0.04 (-0.18%)

USD 3.26B
BHC Bausch Health Companies Inc

-0.01 (-0.11%)

USD 3.23B

ETFs Containing PBH

PSCH Invesco S&P SmallCap Heal.. 3.08 % 0.29 %

+0.50 (+-0.18%)

USD 0.20B
XSLV Invesco S&P SmallCap Low .. 0.00 % 0.25 %

+0.29 (+-0.18%)

USD 0.33B
XST:CA iShares S&P/TSX Capped Co.. 0.00 % 0.61 %

-0.17 (-0.18%)

CAD 0.20B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.80% 88% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.80% 88% B+ 89% A-
Trailing 12 Months  
Capital Gain 12.01% 56% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.01% 56% F 60% D-
Trailing 5 Years  
Capital Gain 148.11% 100% F 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 148.11% 100% F 92% A
Average Annual (5 Year Horizon)  
Capital Gain 16.89% 88% B+ 82% B
Dividend Return 16.89% 88% B+ 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.59% 75% C 52% F
Risk Adjusted Return 78.24% 100% F 94% A
Market Capitalization 2.60B 50% F 71% C-

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 38.00 53% 17%
Price/Book Ratio 2.15 44% 40%
Price / Cash Flow Ratio 14.95 40% 24%
Price/Free Cash Flow Ratio 426.26 6% 0%
Management Effectiveness  
Return on Equity -4.91% 63% 22%
Return on Invested Capital 12.21% 87% 71%
Return on Assets 6.16% 88% 78%
Debt to Equity Ratio 93.00% 36% 39%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector